Sunday, 10 Aug 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    10/08/2025
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    10/08/2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    09/08/2025
    NOTICE OF SETTLEMENT APPROVAL
    NOTICE OF SETTLEMENT APPROVAL
    09/08/2025
    BBBS & Israel’s Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
    BBBS & Israel’s Foresight Awarded USD 5 Million to Build & Commercialize Rugged Autonomous Drones for Hazardous Industrial Environments
    09/08/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • july
  • global
  • Business
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

GlobeNews Wire
Last updated: 16/07/2025 11:19 PM
GlobeNews Wire
Share
6 Min Read
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and  Million of Committed Capital
SHARE
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and  Million of Committed Capital

CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) — Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital. Founded to address urgent unmet needs in rare and life-threatening diseases, Quetzal brings together a team of seasoned executives, scientific pioneers, and biotech & pharmaceutical veterans committed to delivering transformative therapies to patients around the world.

At the core of Quetzal’s mission is a belief that cutting-edge science, guided by proven leadership, can redefine what’s possible in treatment for conditions like Acute Promyelocytic Leukemia (“APL”) and invasive infections. The company has formed around a multi-asset pipeline, initially including:

  • QTX-2101: A novel oral arsenic trioxide therapy for the treatment of APL expected to enter Phase III clinical trials by late 2025, supported by encouraging comparative pharmacokinetic data from a Phase 1b trial sponsored by Syros Pharmaceuticals, Inc.
  • QTX-2102, a next-generation antifungal and antiparasitic therapy in preclinical development, designed to improve efficacy while minimizing toxicity.

Built on Leadership Excellence
Quetzal is led by an executive team with deep expertise in drug development, clinical strategy, and operational execution. “Our team was brought together by a shared conviction: that patients with rare diseases deserve the same urgency and innovation as those with more common conditions,” said Usman Ahmed, CEO. “Quetzal Therapeutics is built to deliver on that promise with the right science, the right strategy, and the right people.”

Usman Ahmed, CEO & Chairman – A proven leader with over two decades of leadership in pharmaceuticals and start-up innovation. During his tenure at Nexus Pharmaceuticals, Usman led the execution of complex transactions, spearheaded operational improvements, and championed cost efficiencies in the highly specialized and challenging field of specialty and generic injectables. 

Dr. Sridhar Desikan, Co-Founder & Chief Scientific Officer – An industry veteran with 28 years of experience in NCE and generics development. Sridhar began his career at Novartis Pharmaceuticals and subsequently worked at DuPont Pharma, Bristol-Myers Squibb, Dr. Reddy’s, and most recently at Nexus Pharmaceuticals as Chief Scientific Officer. Sridhar holds a Ph.D. in Chemical Engineering and has accreditations from Harvard Medical School’s HMX Pro program.

Sara Mathews, Vice President Program Leadership – With nearly 15 years of experience in the biotech industry, Sara is a seasoned asset leader with a proven track record of bringing cross-functional teams together and leading novel oncology therapeutics through global clinical programs from IND filing through late-stage development, filing preparation, and commercial launch planning.

Christina Liwski, General Counsel & CHRO – With over a decade of diverse and sophisticated legal experience, Christina brings deep legal acumen to the team. Christina’s experience spans multiple practice areas, including transactions and litigation. She most recently served as Assistant General Counsel at Nexus Pharmaceuticals, LLC and is admitted to practice in Illinois, Massachusetts, and the United States District Court for the District of Massachusetts.

Guided by an Accomplished Board of Directors
The company’s Board of Directors features industry leaders with a track record of building, funding, and guiding successful companies:

Aman Ahmed – With nearly a decade of experience in the pharmaceutical industry, Aman brings deep expertise in sales operations, DEA and FDA regulatory compliance, international sales, and therapeutic portfolio management. 

Dr. Jonathan Cheng – Dr. Jonathan Cheng is a physician-scientist and oncology drug development expert with a distinguished career across both industry and academia. As Chief Medical Officer at Systimmune, he leads the clinical development of a diverse pipeline of novel therapeutics, including innovative antibody-drug conjugates (ADCs) and the company’s first-in-class EGFR-HER3 bispecific ADC currently in Phase 3 trials.

Todd Chermak, R.Ph., Ph.D – Todd Chermak is a life sciences executive with 30 years of experience spanning the biopharmaceutical, diagnostics, and nutrition industries. He currently serves as Senior Vice President and Global Business Head of Immunology and Proteomics at CellCarta.

Mike Warmuth – Mike Warmuth is currently working on various Boards: for profit, academic, and not-for-profit. From 2018 to 2023 Mr. Warmuth worked for EW Healthcare as an Operating Partner in their New York office. Prior to EW, Mr. Warmuth spent 30 years at Abbott in various senior executive capacities, where he led multiple divisions and business units.

Strategic Talent Acquisition Partnership
Quetzal Therapeutics proudly acknowledges the role of Heidrick & Struggles, a premier global leadership advisory firm, in identifying and recruiting Dr. Jonathan Cheng to the company’s Board of Directors. Their expertise and commitment to excellence were instrumental in securing a highly respected thought leader whose insight will help shape Quetzal’s long-term scientific and clinical strategy.

For more information, please visit: www.quetzaltx.com
Media Contact:
info@quetzaltx.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FIS continues commitment to Para events safety and accessibility with annual site visits
ZKM Launches Ziren, The Endgame for ZK Infrastructure
The Future Now: adidas Reveals the CLIMACOOL LACED
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
TAGGED: and with50%announcedaroundbiopharmaceuticalbuiltcapitalchicagocommittedcompanyconditionsdebutsdiseasesexpertformedfoundedglobehigh-impactjulylaunchleadershipmillionnewlynewsnewswireofficialpatientspipelinequetzalrarerightsciencestrategyteamtherapeuticstodaytogether
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Cisco Unveils Secure Network Architecture to Accelerate Workplace AI Transformation
Business

Cisco Unveils Secure Network Architecture to Accelerate Workplace AI Transformation

10/06/2025
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc – VRNA
Business

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc – VRNA

13/07/2025
NOTICE OF SETTLEMENT APPROVAL
Entertainment

World Peace Concert SOUND OF PEACE: International Benefit Concert for Peace to Take Place for the First Time in Front of the Iconic St. Peter’s Square

22/07/2025
Argon Medical Streamlines Distribution of Product and Enhances Customer Training for Europe, Asia, and Africa with the Debut of a Modern, Mixed-Use Facility
Health

Argon Medical Streamlines Distribution of Product and Enhances Customer Training for Europe, Asia, and Africa with the Debut of a Modern, Mixed-Use Facility

15/07/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?